Real-World heart failure drug study launches in germany

NCT ID NCT06336330

Ongoing Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 32 times

Summary

This study follows over 800 heart failure patients in Germany who are starting dapagliflozin, a drug recently approved for heart failure. Researchers will track how long patients stay on the drug, any side effects, and changes in symptoms and quality of life. The goal is to understand how the drug works outside of clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Aachen, 52062, Germany
Research Site

Alsfeld, 36304, Germany
Research Site

Bamberg, 96049, Germany
Research Site

Bechhofen, 66894, Germany
Research Site

Bergisch Gladbach, 51465, Germany
Research Site

Berlin, 12489, Germany
Research Site

Berlin, 12555, Germany
Research Site

Brilon, 59929, Germany
Research Site

Bruchsal, 76646, Germany
Research Site

Chemnitz, 09113, Germany
Research Site

Dinslaken, 46535, Germany
Research Site

Erfurt, 99084, Germany
Research Site

Erfurt, 99097, Germany
Research Site

Essen, 45128, Germany
Research Site

Frankenthal, 67227, Germany
Research Site

Gera, 07551, Germany
Research Site

Hamburg, 20095, Germany
Research Site

Hamburg, 22087, Germany
Research Site

Hamburg, 22459, Germany
Research Site

Hoppegarten, 15366, Germany
Research Site

Kaiserslautern, 67655, Germany
Research Site

Kitzingen, 97318, Germany
Research Site

Ludwigsburg, 71634, Germany
Research Site

Ludwigshafen am Rhein, 67071, Germany
Research Site

M Hldorf, 84453, Germany
Research Site

Markkleeberg, 4416, Germany
Research Site

Meiningen, 98617, Germany
Research Site

Münster, 48149, Germany
Research Site

Naumburg, 6618, Germany
Research Site

Nuremberg, 90402, Germany
Research Site

Oschersleben, 39387, Germany
Research Site

Papenburg, 26871, Germany
Research Site

Pirna, 01796, Germany
Research Site

Potsdam, 14471, Germany
Research Site

Querfurt, 06268, Germany
Research Site

Ratingen, 40882, Germany
Research Site

Rostock, 18059, Germany
Research Site

Schleswig, 24837, Germany
Research Site

Schwandorf in Bayern, 92421, Germany
Research Site

Schwäbisch Hall, 74523, Germany
Research Site

Siegen, 57072, Germany
Research Site

Steinfurt, 48565, Germany
Research Site

Stollberg, 09366, Germany
Research Site

Straubing, 94315, Germany
Research Site

Stuttgart, 70178, Germany
Research Site

Ulm, 89073, Germany
Research Site

Wermsdorf, 04779, Germany

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dapagliflozin

What this could lead to

If successful, this study could show how well dapagliflozin works for heart failure in everyday practice, helping doctors better manage the condition.

What could go wrong

This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by other factors and may not apply to all patients.

Conditions

The condition(s) this trial relates to.

cardiovascular disorder heart disorder heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASES HEART DISEASES HEART DISEASES HEART FAILURE